Hrinak Donna J
Known title: DirectorCIK: 0001296811
Hrinak Donna J's purchase track record
Hrinak Donna J has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/15/2022 | CVSA | $10K | +31.6% | +59.3% | -3.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 344 | $33K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,445 | $140K | 11/12/2025 | View on chart |
| CVSA | ▼ Sell | Open Market | 915 | $90K | 2/21/2025 | View on chart |
| CVSA | ▼ Sell | Open Market | 4,812 | $497K | 2/14/2025 | View on chart |
| CVSA | ▼ Sell | Open Market | 4,685 | $509K | 2/6/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 1,560 | $140K | 11/13/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 557 | $51K | 11/8/2024 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 645 | $36K | 11/9/2023 | View on chart |
| CVSA | ▲ Buy | Grant | 2,530 | $140K | 11/8/2023 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 812 | $35K | 11/10/2022 | View on chart |
| CVSA | ▲ Buy | Grant | 2,930 | $125K | 11/9/2022 | View on chart |
| CVSA | ▲ Buy | Open Market | 415 | $10K | 2/15/2022 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 962 | $31K | 11/17/2021 | View on chart |
| CVSA | ▲ Buy | Grant | 3,690 | $125K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.